Dana-Far­ber, Brigham breakup could lead to a rip­ple ef­fect for CGT clin­i­cal tri­als for can­cer

Dana-Far­ber Can­cer In­sti­tute an­nounced on Sept. 14 that it is se­cur­ing a new joint ven­ture with Beth Is­rael Dea­coness Med­ical Cen­ter, mark­ing a breakup of its decades­long adult can­cer care part­ner­ship with Brigham and Women’s Hos­pi­tal.

The news shocked Brigham, which had been ne­go­ti­at­ing a part­ner­ship ex­ten­sion with Dana-Far­ber for the past 15 months, ac­cord­ing to the Boston Globe.

There are around 20 on­go­ing cell ther­a­py clin­i­cal tri­als un­der the Dana-Far­ber Brigham Can­cer Cen­ter, which com­pris­es 12 treat­ment cen­ters with ex­perts from Dana-Far­ber and Brigham work­ing to­geth­er. Brigham al­so has its own gene and cell ther­a­py in­sti­tute and a lab ded­i­cat­ed to next-gen­er­a­tion, ge­net­i­cal­ly-mod­i­fied CAR-T cell ther­a­pies for can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER